š
BMY Q3 2020 Earnings Call
November 5, 2020 at 12:00 AM
š
Company
BMY
Quarter
Q3 2020
Date
November 5, 2020 at 12:00 AM
Speakers
2
Word Count
~6,650
Transcript Content
Operator
Good day, and welcome to the Bristol Myers Squibb 2020 Third Quarter Results Conference Call. Todayās conference is being recorded. At this time, I would like to turn the conference over to Mr. Tim Power, Vice President, Investor Relations. Please go ahead sir. Tim Power (Head of Investor Relations): Thanks, Kevin, and good morning everyone. Thanks for joining us this morning for our third quarter 2020 earnings call. Giovanni Caforio (CEO): Thank you, Tim, and good morning, everyone. I hope that you and your families are safe and healthy. Q3 was a very strong quarter across the Company, adding to great performance over the past year. I will go into more details about the quarter in a few moments. But recognizing that it has been almost a year since we established our new Company, I would first like to give you my perspective on the Company overall. Turning to slide 4, a year ago, we transformed our Company with a goal of positioning us for growth in the near, medium and long term. I am very pleased with our ability to consistently deliver on that promise across multiple dimensions. Starting with integration where we continue to make great progress. The strength of our execution as a combined Company is a testament to our successful integration so far. The culture of our Company has been shaped by our values, including a focus on innovation, collaboration, and a great sense of urgency. Our synergy capture is ahead of our original expectations. From a commercial perspective, we have driven strong performance from our in-line brands. We have launched four new medicines including Inrebic, Reblozyl, Zeposia, and Onureg. We have entered the first-line lung cancer market with Opdivo and Yervoy. David Elkins (CFO): Thank you, Giovanni. Hello, everyone. And thanks again for joining our call today. Iām very pleased by the execution of our teams, delivering very strong quarterly and year-to-date results while operating in this global pandemic. Letās turn to slide nine and discuss our top line performance. Third quarter and year-to-date revenues continued to reflect our strong execution, growing 6% versus prior year on a pro forma basis. As you can see, a vast majority of our brands demonstrated robust growth. Tim Power (Head of Investor Relations): Great. Thanks very much, David. Kevin, can we go to our first question, please?
Operator
Certainly. Our first question today comes from Chris Schott of J.P. Morgan.
Speaker
Great. Thanks very much for the questions. And congrats on all the progress youāve made this year. I guess, just two here, maybe first on TYK2. Could you just elaborate a little bit more on the safety profile? I think, thereās still some lingering questions out there of will we see any of maybe some of the JAK-like safety issues? I know youāve talked a lot about that in the past. But just to confirm, did you see any imbalance at all, small or not, on thrombotic events from the study? And just help us a little bit in terms of what the profile is shaping up like, on the safety there? And then, my second question was on Opdivo. Youāre launching a number of adjuvant indications next year. Could you just remind us on those, do you expect that these will have fast uptake, like weāre seeing in some of the metastatic settings, or are these indications that might take a little bit longer to build out over time? Thanks so much. Giovanni Caforio (CEO): Chris, thank you. I think, Iāll start off and then Chris, Iāll pass on to you for the Opdivo-related question. From a TYK2 perspective, first of all, we are very happy with what weāve seen from the result perspective. This is the first of the two Phase 3 trials for TYK1 that has read out. And we have seen not only statistical as well as clinical meaningfulness versus placebo, but also the superiority versus apremilast or Otezla in moderate to severe psoriasis. From what we have seen before from the Phase 2 studies, and weāve talked about the safety profile, we continue to believe in that. There is a differentiated mechanism of action that we believe in. We do think that the TYK2 inhibition, which has a specific downstream effect on IL-12, IL-23 as well as interferon alpha has played out, and we continue to believe in that. Of course, I canāt go into the specifics of the data. They will be presented in the future in the medical meeting. But overall, we are very happy where we are. And I look forward to the readout of the second Phase 3 in the first quarter of 2021. So, hopefully, that answers your question. And let me pass it on to Chris to talk about Opdivo from here on.
Speaker
Sure. Thanks for the question, Chris. We do have a number of exciting opportunities in the adjuvant setting. Iāll maybe just highlight gastric and bladder specifically. As we talked about a few months ago with respect to gastric cancer, weāre excited about the opportunity coming out of CheckMate -577. This is a space where thereās significant unmet need. Thereās very little in the way of systemic therapy thatās used here. And as Samit has previously talked about, those patients who are getting neo-adjuvant chemotherapy and radiotherapy, about three quarters of those patients donāt achieve a pathologic complete response. So, really, there are no great options for those patients. And weāve seen very good efficacy coming out of -577 with a doubling of disease-free survival at a manageable safety profile. And there is relatively clean air here from a competitive standpoint, as weāll be the first immune-oncology drug in the setting for a number of years. With respect to bladder, again, weāre happy with the results that we saw with -274. This is a space with about 6,000 to 7,000 treated patients in the U.S. Again, not a lot in the way of great systemic therapies here. And as weāve said, we met the primary endpoint for Opdivo and look forward to launching in the space. This is again another area where thereās relatively clean air. So, we would expect reasonably aggressive uptake in both of these indications.
Operator
The next question today comes from Seamus Fernandez of Guggenheim.
Speaker
Congratulations on the successful quarter and the progress made. Samit, I have a question regarding the 12-milligram dose for psoriatic arthritis that we are expecting to see data on next week. This is an area where we've seen challenges with other JAK inhibitors. Can you share what we should focus on when reviewing this data? It's about to be presented, and I believe it's something investors are keen to understand. Additionally, as we explore opportunities in conditions like ulcerative colitis, youāve highlighted the IL-23 profile. Is this where your enthusiasm for the product really lies, particularly in ulcerative colitis? Thank you.
Speaker
Thank you, Seamus, for your question. As noted in our press release regarding the POETYK1 readout, the dose utilized in the Phase 3 trial is the 6-milligram dose. The abstract and poster at the ACR for psoriatic arthritis include both the 6 and 12-milligram doses. From a safety perspective, the 6-milligram dose has shown a promising profile. Additionally, the older Phase 2 study indicated very positive results at that dose, which have been echoed in the Phase 3 study. The 12-milligram dose does show a dose response, but, as you pointed out, overall safety management is crucial. We will continue to analyze the data as we prepare for a Phase 3 study in the psoriatic arthritis area. Overall, we are pleased with the 6-milligram dose tested in the Phase 2 study, and we will reevaluate it in the Phase 3 second readout planned for the first quarter of next year. While efficacy is important, we must also consider the benefit-risk balance. Thus, the 6-milligram dose appears to be a reasonable choice from a combined safety and efficacy perspective. Regarding ulcerative colitis, as you mentioned, the differentiation lies in the convenience of oral administration. Weāve already addressed psoriatic arthritis, and we are looking forward to future readouts for the TYK2 program. Itās crucial to demonstrate both efficacy and safety for patients with ulcerative colitis with TYK2. Moreover, the IL-12 and IL-23 inhibition mechanism will significantly impact both ulcerative colitis and future efforts in Crohnās disease.
Operator
The next question comes from Geoff Meacham of Bank of America.
Speaker
Great. Thanks a lot, guys, for the questions. I just had a couple, I think both of them for Chris. So, when you look at the first-line lung trends for Opdivo, Chris, you guys have gained some share, I think 5% or so in the U.S. But, I donāt see much of a trend break this quarter. Was there already reasonable share in first-line lung before the label expansion? And maybe just help us to whatās been the feedback from the ground so far? And the second one on Reblozyl, the sequential trends have been really strong. I know obviously itās early. But, what can you say about the distribution between MDS and beta-thal and maybe just the cadence of uptake between the two indications? Thanks a lot, guys.
Speaker
Maybe Iāll start, and then Iāll turn it over to Nadim to address the second part of your question. So, with respect to Opdivo, let me just first give you the dynamics for the quarter. So, obviously, happy with the sequential growth that we saw for the quarter. That in the U.S. is a function of favorable demand, and Iāll talk about first-line lung, specifically in the second. We also, as David had noted, saw some inventory build. This was partially offset by the impact that weāve seen with the decline in immuno-oncology eligibility that weāve been discussing previously. Thatās mainly in the second-line thoracic indications. And that still is a drag on Opdivo currently. That said, weāre happy to see that weāve got sequential growth for the quarter. And that was in part a function of first-line lung. And with respect to first-line lung, weāre very happy with what weāre seeing with the launches so far in the U.S. The uptake continues to increase steadily. As we noted earlier, the market share is currently in the high single digits. The execution here continues to be very good. So, for example, we have a leading share in first-line lung. And importantly, at this stage of the launch, weāre seeing a nice steady growth in the number of new trials week-over-week. So, overall, weāre happy with the uptake that weāve seen. We knew, as we discussed previously that this was going to be a different set of launches, just given the entrenched dynamics from a competitive standpoint in first-line lung. But, we continue to be very pleased with the teamās performance here. So, maybe Iāll turn it over to Nadim for the second part of your question.
Speaker
Great. Thanks, Geoff, for your question. So, regarding the Reblozyl launch, maybe Iāll just make a couple of points. So, as David said, very pleased with the launch so far, high demand, very good brand awareness, field team is doing really well. And if you remember, we had always said that the predominant use, at least in the U.S., would be MDS, and itās playing out exactly that same way. So, today, the majority use in the U.S. is on MDS patients. And the interesting thing is weāve seen a little bit of a halo effect from beta-thal, but weāve seen a little bit more uptake with beta-thal since the MDS launch. But, the predominant use is still MDS. Now, globally, as we launch across the world, thereāll be different regions where you see a different prevalence profile, beta thalassemia, where itās higher, for example, in Asia, the Mediterranean. But today, in the U.S., Geoff, the predominant use is still MDS, exactly as we had anticipated. Thanks for your question.
Operator
The next question comes from Terence Flynn of Goldman Sachs.
Speaker
Hi. Thanks for taking the questions. I was just wondering, first, on Opdivo for neo-adjuvant lung, if you can give us any update on the regulatory path and when you might know more there, and if youāre confident that you could get approval on the pathological complete response endpoint alone. And then, the second question, you mentioned that the synergies are tracking ahead of your expectations. I guess, just trying to understand how much of the spend is synergies and how much is kind of from a COVID environment? And so, how much of that should we expect to carry forward into 2021? Thank you.
Speaker
Thank you, Terence, for the question, Samit here. As Chris mentioned earlier, there is still obviously a much required need for new medicines in patients with early disease to be able to get into a pathological complete response because that may signal for the long-term benefit for these patients. Now, of course, this is not a validated regulatory endpoint, as you very well said. So, what we are looking forward to now, of course, continuing our dialogue with the regulatory agencies, especially with the FDA, as we also continue to follow these patients for the first data for event-free survival as well. So, we will obviously keep you posted in the future as we make progress. At the current time, we continue our dialogue and continue with the patient follow-up to generate more data. I donāt think we can give clear guidance today in terms of approvability based on the endpoint. And for synergies, I think David or Giovanni? Giovanni Caforio (CEO): Yes. David, why donāt you go ahead? David Elkins (CFO): Yes. Terence, thanks for the question. Look, weāve been very pleased with our ability to capture synergies so far this year. And weāre really encouraged to see that our synergy capture is actually tracking ahead of our original expectations for this year. So, weāll provide further insight into that on our expectations of the overall synergy achievement after we close the year, but things are going very well.
Operator
The next question comes from Tim Anderson of Wolfe Research.
Speaker
I have a question on going back to TYK2. So, I think, most investors view the value proposition in psoriasis relative to Otezla being better efficacy. But, weāve wondered if better tolerability could also be a differentiator, because with Otezla, thereās GI side effects that require dose titration, and your drug doesnāt require dose titration. And at least in Phase 2, there were no GI side effects. So, when we see the full Phase 3 results, might we also see better tolerability as yet another area of differentiation, beyond just oral dosing and beyond better efficacy?
Speaker
Thank you, Tim, for the question. As we said, if you look at the overall trial design for this one as well as for the next study to be followed, the good news is that there is a comparison, not only versus placebo but also the comparison versus Otezla. And so, there will certainly be an opportunity to contrast and compare not only the efficacy, but all of the tolerability or safety as we talk about. And those are going to be very important from a patient perspective and physician perspective, from a convenience perspective. Certainly, these will have implications from a commercial perspective. And let me pass it on to Chris to comment on that.
Speaker
Yes. Thanks for the question, Tim. I mean, I think, as we said previously, weāre excited about the opportunity that we have here, based on the data that we see coming out of POETYK. I think, we have a real opportunity to establish TYK as the frontline branded oral choice for these moderate to severe patients. What I would say, just to build on what Samit mentioned, is that this is a market where in spite of new biologics coming into the space, dermatologists continue to believe in an ascending treatment algorithm. So, they typically start with topical, they move to oral, then they go to injectables. And it is also a market, as I think you point out, where patient preference drives choice. So, you do see a very strong focus on safety concerns, needle phobia is an issue here. And we think these dynamics really play to the profile that we have with TYK2, very strong efficacy in an oral formulation, a novel mechanism of action, and a favorable tolerability and safety profile. And so, we think weāve got a real opportunity here to establish TYK as the leading oral in the space.
Operator
The next question comes from Andrew Baum of Citi.
Speaker
Thank you. Couple of questions, please. First on Otezla. As you think about marketing, is it positioned to displace Otezla as the oral agent of choice, given the efficacy, tolerability, or to what extent can you actually seek to slow or defer the initiation of therapy with biologics? And then, second, perhaps you could just give us the market shares in non-small cell for 227, 9LA in the U.S. in the first-line setting. Giovanni Caforio (CEO): Chris?
Speaker
Sure, Andrew, thank you for your question. Regarding Otezla and the TYK opportunity in psoriasis, I would refer back to my earlier response. We believe that TYK has the potential to become the preferred oral treatment for moderate-to-severe patients in this area based on the data we have. This reflects the tendency of dermatologists to opt for less burdensome treatment methods while seeking maximum efficacy. Safety remains a significant concern, and we see a chance to replace existing oral therapies before biologics are considered. Additionally, we believe there is an opportunity to provide effective treatment options before patients advance to biologic therapies. It's important to note that only about 15% of patients eventually receive biologics, even with the introduction of new biologics in the market. Therefore, we see the potential to achieve both objectives. Regarding the first-line lung market share, as previously stated, we currently hold a market share in the high single digits. The 227 regimen is primarily used for patients with PD-L1 levels of 49%, and we are seeing increasing use of the 9LA regimen, mostly among patients with PD-L1 levels below 1 and those who are PD-L1 negative.
Operator
The next question comes from Luisa Hector of Berenberg.
Speaker
Hello. I wonder, now we have the ASH abstract, whether thereās anything youād like to point out from the various data sets youāre presenting, and any particular update from durability of response? And then, ide-cel and liso-cel, any update you can give from the FDA review? Thank you.
Speaker
Sure. Thank you. Let me start with ASH and then move on to liso-cel and ide-cel. If Nadim would like to add something, that would be great. From the ASH perspective, over the past few years, both Celgene and BMS have been present with data. Based on past presentations, these medicines have progressed to late-stage development, and we are continuing to gather more data. There are a few key abstracts being presented. Firstly, the activity of liso-cel as a single therapy and in combination, particularly for patients receiving ibrutinib and venetoclax in CLL, is quite significant. The overall response rate, tolerability, and durability in these patients continue to evolve, especially considering the future needs of patients with CLL who have been treated with ibrutinib and venetoclax, highlighting the necessity for subsequent therapies in case of recurrence or relapse. Another important data set is the triple combination of iberdomide with daratumumab and dexamethasone, alongside Velcade and dexamethasone. These represent advancements in the data, and we will monitor how it develops, but it is clear that response rates will be impacted as we aim to move iberdomide into earlier settings, guiding our future steps. We are pleased with the progress and will delve deeper into it, with plans to continue our focus on CELMoDās trials for iberdomide and advancing other CELMoDs, as mentioned by Giovanni earlier. Regarding liso-cel, thereās not much new to share, but we continue our discussions with regulatory agencies. An inspection of the facility in Washington has been completed, and we previously communicated that there are no scheduled inspections for the second, independent facility. Liso-cel has a PDUFA date of November 16, and for ide-cel, we are also in ongoing discussions with a PDUFA date set for March 27, 2021. That covers our current status. Nadim, would you like to add anything or Giovanni?
Speaker
No. I think you covered it well, Samit. Thanks. Giovanni Caforio (CEO): The only thing I would add is, just to close on what Samit mentioned regarding liso-cel, we will update you as our discussions with the regulatory authorities progress.
Operator
The next question comes from Dane Leone of Raymond James.
Speaker
Hi. Thank you for taking the questions. And congratulations on all the progress. Just some quick ones for me. When do you think you would be able to disclose the actual pathologic complete response rate for the 816 study? And if that would still be a nondisclosure item for you until regulatory discussions are complete? Could you at least give us how the study was powered on that endpoint, so we can make our own assumptions on how the chemo arm would perform and then how the combo arm probably would have performed, to start? And then, in terms of iberdomide, do you have a longer timeline now in terms of path to pivotal studies and when that could actually get to market? I think, a lot of us in the clinical community as well are thinking about this as an offset to Revlimid and the patent expirations there. So, any kind of longer term insight you might be able, given the development path would be super helpful. Thank you.
Speaker
Thank you for the question. So, let me start with the pCR part. So certainly, weāre going to look for an opportunity for a proper presentation of the data at a future medical meeting. That is not dependent on the regulatory aspects because itās an independent endpoint that can certainly be discussed. So, weāre looking to that. I think, the trial details, we have not shared the statistical analysis plan per se in terms of the assumptions made for the calculation at this time. So, weāll not be able to share that. But certainly, there is a previous data that had been presented and published for chemotherapy leading to pCR responses. So, you can assume that. Now, what differences will be important in terms of a delta between chemotherapy and then the combination of nivolumab, those are the types of discussions weāll need to continue to have with the regulatory agencies as to what becomes meaningful. So, as the dialogue evolves and once the decisions are made, weāll certainly communicate that with you. From the iberdomide perspective, the first line plus study is already ongoing as we said. And as Iāve just mentioned previously, as the data continues to evolve and weāll have the data readout sometime next year, those will be trigger points for us to discuss that single agent combination dexamethasone, discussions with the regulatory agencies to see if the data would suffice for a regulatory dialogue in the first line plus setting. And then has the data evolved for the doublets and the triplets in the earlier setting, then weāll launch later line trials as well in the earlier settings. Nadim, do you want to add something to that?
Speaker
Sure. I would just add a couple of points maybe. So, thanks, Dane, for your question. The point that Samit had made, our plan had always been to move from the doublet to the triplet, which is, as you know, very important, especially in relapsed and newly diagnosed disease. So, having these data at ASH will be an important foundation on how we move the treatment up from the late-line setting to early relapse setting and then ultimately, newly diagnosed setting since you had asked the question about Revlimid and the impact in the future. So, we have a very clear development plan. As Samit said, of course, we have to pass all the clinical gates as we go through. But, the starting point is the triplet data that weāre seeing at ASH now. So, weāre excited about the opportunity moving forward. Thanks for your question.
Operator
The next question comes from David Risinger of Morgan Stanley.
Speaker
Yes. Thank you very much. So, I have two questions, please. First, could you provide more color on what you need to discuss with the FDA on liso-cel? It seemed to me that discussion should be over by this point. And a follow-on to that is, are there any issues with the recent manufacturing inspections, or do you have confidence following those manufacturing inspections? And then, the second question is, other BCMA ADCs have been associated with ocular toxicity in multiple myeloma. Do you expect a differentiated profile for your BCMA CC-99712? And, when should we expect to see data? Thank you.
Speaker
Thank you for your question. Regarding liso-cel, as we previously mentioned, the FDA has communicated that both our facilities in Washington and Texas require inspection. Currently, they have inspected our plant in Bothell, Washington, but the inspection of the second plant has not yet been scheduled. The FDA is taking precautions to ensure the safety of their staff during the COVID pandemic, which impacts travel scheduling. We respect their plans regarding inspections. We've had positive discussions with the agencies and are hopeful for approval soon so we can provide treatment to patients. We will update you as soon as we receive a decision. While we will not comment specifically on inspection talks, we are pleased with the ongoing communication. On the ADC for multiple myeloma, we are in the early Phase 1 stage. Itās too early to determine if we will achieve a unique profile, but we are mindful of the ocular toxicity concern and will continue to assess patients for that. We anticipate the first data will be available late next year as we are still in the dose escalation phase. Once the data reaches maturity, we will present it at a medical conference and share it with you.
Operator
Next question comes from Gregg Gilbert of Truist.
Speaker
Giovanni, youāve made it very clear that cardiovascular is a core franchise for the Company. On Factor XIa, what do you think you have to deliver in terms of clinical profile to enable that asset to add value in what will eventually be a generic environment? And then, maybe more strategically, in cardiovascular, it looks like you have at one end of the spectrum kind of a mass market Eliquis and Factor XIa approach, and on the other hand, a more specialized approach with MyoKardia. So, I assume your strategic vision in cardiovascular spans across that. But, curious if you want to be more focused in one end or the other as you consider additional business development in cardiovascular. And then, a follow-up for David. How would you describe the LOE step-down for Revlimid in the coming years? And do you think the Street has that right, at least in general in terms of how itās being modeled? We obviously have imperfect information. Thank you. Giovanni Caforio (CEO): Let me start by addressing your question about cardiovascular and Factor XIa. First, I want to emphasize that cardiovascular is strategically important to us, and this has been a consistent focus for the Company. I'm proud of our efforts with Eliquis and our ability to develop unique assets in this area. We take a distinct approach in demonstrating the value of these assets, as shown with Eliquis through real evidence, and maximizing the value of our medicines. Looking at Eliquis, mavacamten, and a Factor XIa inhibitor, we feel confident in our execution and commitment in cardiovascular. The approaches differ between broader assets like Eliquis and Factor XIa, where we chose to partner to enhance our reach into the primary care market and support the development of assets needing substantial investment across various indications. Mavacamten represents a more precision-focused effort in cardiovascular, aligning closely with our R&D strategy and our early pipeline in heart failure. It's not necessarily about one approach versus another; rather, itās about recognizing cardiovascular as a field with significant unmet needs, where the Company has shown excellent execution capabilities. We tailor our approach based on what each asset requires for maximum value and where BMS excels. MyoKardia is an intriguing acquisition because its precision approach aligns well with our R&D strategy. Now, Iāll turn it over to Samit for any additional insights on Factor XIa, particularly regarding differentiation and our development strategy, and then we can address your question about Revlimid.
Speaker
Thank you, Giovanni. The one thing that I would also add on mavacamten, remember, patients with obstructive hypertrophic cardiomyopathy, the ones that are symptomatic, the ones that we are talking about from a treatment perspective, also have arrhythmia, especially atrial fibrillation that they experienced. So, Eliquis is used there as well, and many cardiologists are very well aware of need of Eliquis. And certainly in the future when mavacamten potentially might be available, it would be very helpful for these patients. Coming back again then on to the anticoagulation and Factor XIa, I think certainly very happy that we are in that stage and with the Eliquis, what we have done. There are two things that are going to be important to remember is, number one, there are still bleeding risks and patients donāt necessarily get treated with true doses of currently available treatments, and some patients are not even treated because of the bleeding risk. The second unmet medical need is that patients cannot be treated on top of their background antiplatelet therapies for indications such as secondary strokes. And that is a very high unmet medical need, and patients who have had a first stroke are at very high risk of experiencing a second stroke, maybe even 50% to 60% probability. And therefore, what weāre looking for in the Factor XIa development program, as we look at the Phase 2 studies that are currently ongoing is number one, the decrease in the bleeding probabilities; and second, the combinability that background therapy of antiplatelet agents and the secondary stroke prevention study that is currently ongoing in terms of its enrollment. So, those are the important aspects that will make us go into the Phase 3 development program once the data are available. Let me pass it on to David to comment further on the Revlimid side. David Elkins (CFO): We made great progress this year on the IP front, both with Revlimid as well as with Eliquis. And as you know, we settled with Dr. Reddyās. We have the settlement with Natco, which just to remind you, remember, the Natco agreement is a single-digit volume entering 2022, which grows to about a third by 2025. And we have some other settlements, which arenāt public with Dr. Reddyās and Alvogen. But, as we clearly see it more as a slope, not as a cliff, starting in 2022 with full generic entry coming in ā26. And at the time we did the acquisition, all Iād say is that we took a more conservative view on Revlimid than the sell-side equity analysts did at that time. So with that said, we still believe Revlimid will add potential significant cash flow for the business over that period from ā22 through ā25. Giovanni Caforio (CEO): Thank you, David. To address your question, during the period from 2022 to 2026, we expect Revlimid's performance to follow a gradual decline, starting from a strong position. Our confidence in the strength of our intellectual property has been reinforced by the outcomes weāve experienced, including the IP that wasn't granted and the settlements mentioned by David. Furthermore, our business has continued to perform well beyond just revenue, and the advancements in our pipeline give us confidence in our ability to refresh our portfolio. As I stated earlier, I am optimistic about our capacity to maintain strong performance while we navigate the loss of Revlimid's exclusivity. This has been our goal from the beginning, and our execution so far has been effective, making me confident in our future success during this transition.
Operator
The next question comes from Matt Phipps of William Blair.
Speaker
Thanks and congratulations on a solid quarter. I wanted to ask if, following the POETYK psoriatic study, you plan to explore moving this asset into a milder patient setting, similar to the recent advanced study. Additionally, I have a quick question regarding the Forbius acquisition. Could you compare and contrast the use of a TGF-beta monoclonal antibody combined with Opdivo versus a bispecific molecule like the one you track that is combined with the PD-L1 antibody?
Speaker
Thank you for the questions, Matt. First of all, on the TYK2 aspect, so you know that we are very happy with the results from the POETYK1 study. You also know that there is a broad program already underway where we have the evaluation ongoing in psoriatic arthritis and lupus, systemic lupus erythematosus, lupus arthritis as well as the inflammatory bowel disease. Mild psoriasis, we certainly have an eye on it. We obviously think about this as we evolve with the data on psoriasis, we have to look at the overall efficacy and safety profile in the second study also readout. And that will dictate where we go next in terms of evaluation of deucravacitinib in psoriasis and other indications related to psoriasis. On the TGF-beta front, we are of course, aware of the bispecific TGF-beta PD-1 that the competitors have. When we look at TGF-beta, the specificity of the inhibition caused by this particular entity is very important. And we certainly will look at the combination with our own pipeline, not only with nivolumab, but we also have relatlimab, as you know, in development. So, weāll be looking at all those combinations as the Phase 1 study did evolve, and we get to see what the dose and the schedule will be for dosing patients with oncologic indications, and that will pave the way for the combination strategies looking forward. I think having the ability to give two drugs separately will give us more opportunities for combination strategies looking forward.
Operator
The last question today comes from Carter Gould of Barclays.
Speaker
Great. Good morning, guys. Thanks for taking the question. Congrats on the quarter. I guess, first, a competitor in the TIGIT space that is perceived to be most closely related to you with also an Fc mutated region, discontinued their program recently. In the past, youāve been relatively sort of balanced language on the outlook for this program. Any change or updates on how you see there? Any commentary on that discontinuation or differentiation that maybe the Street doesnāt appreciate between those two programs? And then, maybe coming back to the CELMoDs again. Should we think about the iberdomide decision sort of running independent for 92480, or is there going to be a decision to be made at some point next year where you need to sort of pick a winner or can they coexist? Thank you.
Speaker
Sure. Thank you, Carter. I think, great questions. First of all on the TIGIT side, we certainly have seen the announcement from the competitor from discontinuation of the program on the side. And we donāt know the details and the structure of their molecule, etc. But certainly, we have our own molecule, which is in Phase 1 study. We also have been looking at to see where we go with the combination very early on to be able to define the path forward. As the data evolves, weāll certainly update you and others in terms of where we go or what the fate of the program will be. But, it is too early to say from our own perspective, the specificity of inert Fc portion or inactive Fc portion, I think needs to be further investigated before a decisive decision can be made on that side. So, more to follow on TIGIT in the future. On the CELMoDs and iberdomide side, as we said, both of our programs are in development. Iberdomide is a little bit further because it started earlier. 480 is a very potent molecule. We shared the data of 50-plus-percent of overall response rate with 480 plus dexamethasone in the line setting. Both of those studies are in the development setting. But if you recall, the overall development of IMiD in the past, Revlimid and pomalidomide, how they were developed in the organization, how Revlimid then set up in the upfront setting and pomalidomide then became a preferred molecule for the second, third-line patient population. So, we have to keep that in mind as we continue to evolve. And we also have the good position that we have a lot of data available from a multiple myeloma perspective that we can actually investigate to see what is the mechanism where these drugs will fit the best, what opportunities we may be able to avail in terms of combination strategies with our own pipeline, looking at the platforms that we already have, not only with CELMoDs, but also from the T-cell engager, from CAR-T cell therapy as well as the evolving ADC platform. So, those opportunities, because of the few CELMoDs we have in our hand can certainly be further investigated in a broader way, rather than limiting ourselves to a singular CELMoD. But let me ask Nadim to add anything he wants to further elaborate on this. Thank you.
Speaker
Sure. Thanks, Samit, and thanks, Carter, for your question. So, I think, right now, weāre very pleased with the early data weāre seeing for both. And as Samit said, weāve done the same with Revlimid and Pomalyst in the past. So, there are discrete patient segments with very different clinical needs where you could potentially see the coexistence of both CELMoDs. So, for example, the maintenance setting, a CELMoD with a better tolerability profile. In relapsed setting with high-risk disease, you could see a more potent CELMoD come through. So, I think weāre going to continue to look at the data but weāre pleased with how both are progressing. And then, as Samit said, one of our key objectives is to come up with this multi-modality combination approach. So, you can envisage a CELMoD plus BCMA through multiple lines of therapy as patients progress from newly diagnosed disease to late-stage disease. And weāve already seen the use of sequential treatment through the current CELMoDs, or I should say, with Revlimid and Pomalyst. So, we do think that the combination of BCMA and CELMoDs across lines of therapy, a different patient segment could be really important, both clinically and commercially. So, thanks for your question. Giovanni Caforio (CEO): Thank you. Thank you, Nadim. And thanks to all of you for joining our call today. We have a lot to discuss, and I think that speaks to breadth and depth of our business, and importantly, our pipeline. So, as we discussed, itās been a really active year and a very, very exciting first year for a new company. And I can say with confidence that Bristol Myers Squibb today is in a really strong position with significant near-term launch opportunities and a substantial pipeline to address unmet needs of patients that will position us very strongly and very well for the future. So, thanks again for joining us. And as always, our team will be able to answer further questions you may have. Have a good day. Thanks, everyone.
Operator
Ladies and gentlemen, that concludes todayās conference call. Thank you for your participation. You may now disconnect.
Need more earnings data?
Explore more earnings information and financial data for BMY
Transcript sourced from Financial Modeling Prep (FMP)